Restless Legs Syndrome: Drugs That Cause or Treat It

What Restless Legs Syndrome Actually Is

RLS is a sensorimotor disorder defined by an irresistible urge to move the legs, typically accompanied by uncomfortable sensations that worsen during rest and improve with movement. Symptoms follow a circadian pattern, peaking in the evening and early night hours. The International Restless Legs Syndrome Study Group (IRLSSG) requires all five diagnostic criteria to be met before a diagnosis is made.

The condition affects between 5% and 15% of adults in Western populations, though only 2-3% experience symptoms severe enough to require pharmacotherapy [1]. Women are affected roughly twice as often as men, and prevalence increases with age. RLS runs in families: first-degree relatives of affected individuals carry a 3- to 6-fold increased risk compared to the general population [2]. Genome-wide association studies have identified variants in MEIS1, BTBD9, and MAP2K5 as contributors to heritable risk [3].

Two distinct phenotypes exist. Early-onset RLS (before age 45) tends to progress slowly and shows strong familial clustering. Late-onset RLS progresses faster, correlates more tightly with low iron stores, and is more frequently secondary to medications or comorbid conditions. This distinction matters because late-onset, drug-induced RLS may resolve entirely once the offending medication is stopped.

How RLS Is Diagnosed

Diagnosis is entirely clinical. There is no blood test, imaging study, or polysomnography finding that confirms RLS. A physician applies the five IRLSSG consensus criteria: an urge to move the legs usually accompanied by uncomfortable sensations, symptom onset or worsening during rest, partial or complete relief with movement, worsening in the evening or night, and symptoms not solely accounted for by another condition [4].

Lab work serves a supporting role. Serum ferritin and transferrin saturation should be checked in every new RLS patient because iron deficiency is the single most correctable contributor [5]. A ferritin level below 75 mcg/L warrants iron repletion regardless of whether the patient meets criteria for frank anemia. Thyroid function, renal function (BUN, creatinine), and a basic metabolic panel help exclude secondary causes. Hemoglobin A1c screening is reasonable given the association between peripheral neuropathy and RLS-like symptoms.

Polysomnography is not required for diagnosis but can identify periodic limb movements of sleep (PLMS), which occur in roughly 80% of RLS patients. PLMS alone, without the subjective urge to move, does not constitute RLS. The distinction matters for treatment selection because PLMS without RLS does not respond reliably to the same pharmacotherapy.

Drugs That Cause or Worsen Restless Legs

Several widely prescribed medication classes can induce or intensify RLS symptoms. Recognizing these culprits is the single fastest path to relief because discontinuation or substitution may eliminate symptoms entirely.

Antidepressants are the most common offenders. SSRIs (sertraline, fluoxetine, paroxetine, citalopram) and SNRIs (venlafaxine, duloxetine) worsen RLS in approximately 9-28% of users according to a systematic review published in the Journal of Clinical Sleep Medicine [6]. Mirtazapine, despite its sedating profile, also aggravates RLS. The one consistent exception is bupropion, which has mild dopaminergic activity and does not appear to worsen RLS. Some case reports suggest bupropion may actually improve symptoms.

First-generation antihistamines (diphenhydramine, doxylamine, hydroxyzine) cross the blood-brain barrier and block central histamine receptors. Many over-the-counter sleep aids contain diphenhydramine, which patients may not recognize as a potential trigger. Second-generation antihistamines like cetirizine and loratadine carry lower risk because of limited CNS penetration, though case reports of worsening exist [7].

Dopamine antagonists represent the most pharmacologically predictable trigger. Metoclopramide (used for nausea and gastroparesis), prochlorperazine, and first-generation antipsychotics directly block D2 receptors in the basal ganglia. Even second-generation antipsychotics with D2 antagonism (quetiapine, olanzapine, risperidone) can precipitate or worsen RLS [8]. Ondansetron, a 5-HT3 antagonist without significant dopamine blockade, is a safer antiemetic choice for patients with known RLS.

Other notable triggers include lithium, phenytoin, and levothyroxine at supratherapeutic doses. Alcohol and caffeine do not directly cause RLS but lower the symptom threshold in predisposed individuals.

Iron: The Foundation of Every RLS Treatment Plan

Iron repletion is not optional. It is the mandatory first step. Brain iron deficiency is central to RLS pathophysiology, even when peripheral iron markers appear normal. Autopsy and MRI studies show reduced iron content in the substantia nigra of RLS patients compared to controls [9]. The current consensus threshold for treatment is a serum ferritin below 75 mcg/L, a value well above the 12-15 mcg/L cutoff used for diagnosing systemic iron deficiency anemia.

Oral iron replacement uses ferrous sulfate 325 mg (65 mg elemental iron) taken every other day with vitamin C on an empty stomach. The every-other-day dosing schedule comes from research showing that daily dosing upregulates hepcidin, which paradoxically reduces iron absorption on consecutive days [10]. Patients should avoid taking iron within two hours of calcium, antacids, or proton pump inhibitors.

For patients who fail oral therapy (ferritin remains below 75 mcg/L after 12 weeks) or cannot tolerate GI side effects, intravenous iron is the next step. Ferric carboxymaltose 750 mg IV given as two doses one week apart, or low-molecular-weight iron dextran 1,000 mg as a single infusion, are standard regimens. A randomized controlled trial of IV ferric carboxymaltose in RLS patients with ferritin between 75 and 300 mcg/L and transferrin saturation below 45% demonstrated significant improvement in IRLS severity scores at 12 weeks compared to placebo [11].

Rechecking ferritin 8-12 weeks after completing an oral course, or 4-8 weeks after IV infusion, guides whether repletion succeeded. Some patients need maintenance iron therapy indefinitely.

First-Line Pharmacotherapy: Alpha-2-Delta Ligands

The American Academy of Sleep Medicine (AASM) and the IRLSSG both position alpha-2-delta calcium channel ligands as first-line agents for moderate-to-severe RLS that persists after iron repletion [12]. This represents a major shift from earlier guidelines that favored dopamine agonists.

Gabapentin enacarbil (Horizant) is the only alpha-2-delta ligand with an FDA-approved indication specifically for RLS. The approved dose is 600 mg taken once daily at approximately 5 PM with food. In a 12-week randomized trial (N=222), gabapentin enacarbil 600 mg reduced IRLS total scores by 13.2 points versus 8.8 for placebo (P<0.001), with significant improvements in sleep quality and daytime functioning [13]. Unlike standard gabapentin, the enacarbil prodrug formulation provides more predictable absorption from the GI tract.

Pregabalin (Lyrica) does not carry an FDA indication for RLS but has strong evidence from randomized trials. Allen et al. published a 52-week study (N=719) comparing pregabalin 150 mg, 300 mg, and pramipexole 0.5 mg. Pregabalin 300 mg produced IRLS score reductions comparable to pramipexole at 12 weeks, with significantly lower rates of augmentation over one year (2% vs. 8%) [14]. Pregabalin also improved sleep architecture metrics that dopamine agonists did not.

Standard gabapentin (off-label, 300-1,800 mg nightly) is sometimes used when cost is a barrier, but its nonlinear absorption kinetics mean that higher doses yield diminishing bioavailability. Splitting into divided doses can partially compensate.

Side effects across this class include sedation, dizziness, peripheral edema, and weight gain. These medications carry a Schedule V classification (pregabalin) or are unscheduled (gabapentin, gabapentin enacarbil) depending on jurisdiction. Dose reduction is required in renal impairment.

Dopamine Agonists: Effective but Risky

Ropinirole and pramipexole remain FDA-approved for moderate-to-severe RLS but have been downgraded from first-line to second-line status because of augmentation, the paradoxical worsening of RLS symptoms caused by the very drug used to treat them.

Ropinirole is started at 0.25 mg taken 1-3 hours before bedtime, titrated up to a maximum of 4 mg. The key TREAT RLS 1 trial (N=381) showed ropinirole reduced IRLS scores by 11.2 points versus 8.7 for placebo at 12 weeks [15]. Pramipexole is started at 0.125 mg, titrated to a maximum of 0.5 mg. Both agents carry nearly identical efficacy profiles in head-to-head comparisons.

The augmentation problem is not hypothetical. A 10-year prospective study published in Sleep Medicine found that 68% of patients on long-term dopamine agonist therapy developed augmentation [16]. Augmentation manifests as earlier symptom onset in the day, spread of symptoms to the arms or trunk, shorter duration of medication benefit, and paradoxically more intense symptoms overall. Once augmentation develops, the instinctive clinical response (raising the dose) makes the problem worse.

The IRLSSG Task Force published a prevention and management algorithm for augmentation in 2016. Key principles: use the lowest effective dose, keep ropinirole below 1 mg and pramipexole below 0.5 mg, ensure ferritin is above 75 mcg/L, and switch to an alpha-2-delta ligand at the first sign of augmentation rather than escalating the dopamine agonist dose [17].

Impulse control disorders (pathological gambling, compulsive shopping, hypersexuality) affect an estimated 6-17% of patients on dopamine agonists for RLS. Clinicians should screen for these behaviors at every follow-up visit.

Second-Line and Refractory Treatments

When alpha-2-delta ligands and low-dose dopamine agonists fail, or when augmentation has rendered dopamine agonists unusable, several options remain.

Low-dose opioids have been studied in refractory RLS. A 2013 randomized controlled trial of prolonged-release oxycodone/naloxone (mean dose 22.1 mg oxycodone) showed a 16.5-point reduction in IRLS scores versus 9.4 for placebo over 12 weeks (N=304) [18]. The AASM lists opioids as a treatment option for refractory cases with appropriate monitoring and risk stratification. Given the opioid crisis context, this option requires informed consent, opioid agreements, and periodic reassessment.

Rotigotine transdermal patch (1-3 mg/24h) offers continuous dopaminergic stimulation through the skin, which may reduce augmentation risk compared to oral dopamine agonists because of more stable plasma levels. A 6-month trial (N=505) showed sustained IRLS score improvements with the 2 mg and 3 mg patches [19]. Application site reactions occur in approximately 25% of patients.

Benzodiazepines (clonazepam 0.5-2 mg) are sometimes used for RLS-associated insomnia but do not reduce the sensory or motor symptoms themselves. They carry dependence risk and are not recommended as monotherapy.

Intravenous iron can be revisited in treatment-resistant cases, even when ferritin is above 75 mcg/L, if transferrin saturation is below 45% or MRI suggests central iron deficiency. Some specialists empirically trial IV iron regardless of peripheral markers in truly refractory patients.

"For the patient with augmentation on a dopamine agonist, the treatment is not a higher dose. It is a complete drug switch, typically to an alpha-2-delta ligand, combined with iron repletion and a 10-day bridge with a low-dose opioid if withdrawal symptoms are severe," according to IRLSSG consensus guidelines [17].

Drugs to Avoid if You Have RLS

Prescribers managing other conditions in patients with known RLS should maintain an active avoid list. The table below summarizes the highest-risk medications and their safer alternatives.

For depression: Avoid SSRIs and SNRIs when possible. Bupropion is the preferred antidepressant. Trazodone at low doses (25-50 mg) is sometimes tolerated but should be monitored [6].

For nausea: Avoid metoclopramide and prochlorperazine. Ondansetron (Zofran) does not block dopamine receptors and is a safer choice.

For allergies and sleep: Avoid diphenhydramine and doxylamine. Second-generation antihistamines (cetirizine, fexofenadine) carry lower risk. For sleep specifically, consider melatonin, suvorexant, or cognitive behavioral therapy for insomnia rather than antihistamine-based OTC products [7].

For psychosis or bipolar disorder: Avoid first-generation antipsychotics and high-D2-affinity second-generation agents when alternatives exist. Aripiprazole, a partial D2 agonist, may have a more favorable profile for RLS than full D2 antagonists, though evidence is limited.

For gastroparesis: Avoid metoclopramide. Domperidone (available outside the US) does not cross the blood-brain barrier as readily and is less likely to trigger RLS.

When to Refer to a Sleep Specialist

Primary care physicians can manage most mild-to-moderate RLS. Referral to a sleep medicine or movement disorder specialist is appropriate when: symptoms persist despite iron repletion and a trial of first-line medication, augmentation develops on a dopamine agonist, the diagnosis is uncertain (symptoms are atypical or the patient does not meet all five IRLSSG criteria), or the patient requires opioid therapy for refractory RLS.

A specialist may order advanced testing such as suggested immobilization testing (SIT), which quantifies periodic leg movements during forced wakefulness and can help distinguish RLS from peripheral neuropathy, akathisia, or positional discomfort. Polysomnography may be added if concurrent sleep apnea is suspected, since PLMS arousals and apnea-related arousals can mimic each other.

Pregnancy-associated RLS deserves special mention. RLS affects 10-34% of pregnant women, typically peaking in the third trimester and resolving within weeks postpartum [20]. Iron and folate repletion are first-line. Pharmacotherapy options are limited because dopamine agonists and alpha-2-delta ligands lack adequate safety data in pregnancy. Non-pharmacologic measures (pneumatic compression devices, moderate exercise, sleep hygiene) are the mainstay.

Patients with RLS secondary to end-stage renal disease on dialysis represent another complex population. Their RLS is driven partly by uremic toxin accumulation and partly by iron deficiency. IV iron is preferred over oral in dialysis patients. Gabapentin dosing must be adjusted for renal clearance. Kidney transplantation resolves RLS in the majority of affected dialysis patients [21].

Non-Drug Strategies That Have Evidence

Pharmacotherapy is not the only approach. Several non-pharmacologic interventions have randomized trial support, and combining them with medication often produces better outcomes than either alone.

Moderate aerobic exercise (30-minute sessions, three times per week) reduced IRLS severity scores by 40% in a small randomized trial of 28 patients over 12 weeks [22]. Vigorous exercise close to bedtime can worsen symptoms in some individuals, so morning or early afternoon sessions are typically recommended.

Pneumatic compression devices (sequential leg compression for 30-60 minutes before bed) showed significant symptom improvement compared to sham compression in a randomized crossover trial published in Chest [23]. These devices are available by prescription and may be covered by insurance.

Sleep hygiene optimization (consistent sleep-wake schedule, cool bedroom temperature, avoidance of alcohol and caffeine after noon) is recommended by every major guideline. These measures alone will not resolve moderate-to-severe RLS, but they lower the symptom threshold and may reduce medication requirements.

Cognitive behavioral therapy adapted for insomnia (CBT-I) addresses the conditioned arousal and sleep anxiety that frequently accompany chronic RLS. No large trial has tested CBT-I specifically for RLS-related insomnia, but expert opinion supports its use as an adjunct.

The AASM clinical practice guideline recommends discussing non-drug strategies with every RLS patient before initiating pharmacotherapy and continuing them alongside medication when drugs are added [12].